Acromegaly Treatment Market 2027 By Therapeutics, Mechanism of Action, Distribution Channel and Geography | The Insight Partners

Acromegaly Treatment Market to 2027 - Global Analysis and Forecasts By Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Others); Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers, Others); Distribution Channel (Hospital Stores, Retail Pharmacy Store, Online Pharmacy) and Geography

Report Code: TIPRE00005553 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Acromegaly is a hormonal disease caused due to excess production of growth hormone by pituitary gland in adults and affects the physical appearance and internal organs of patients. It is generally caused by benign pituitary tumor. Some of the symptoms of acromegaly are enlargement of feet and hands, also it may cause changes in shape of face. The acromegaly may lead to many health problems such as goiter, cardiovascular disorders, hypertension and others.

MARKET DYNAMICS
The acromegaly treatment market is expected to grow in coming years owing to factors such as rise in genetic disorders, increase in incidences of hormonal diseases such as hypopituitarism and endocrine diseases, advancement in technology and investment in R&D technique for drug development and others. On the other hand there are number of drug in pipeline for the treatment of acromegaly is likely offer opportunities for market growth.

MARKET SCOPE
The "Global Acromegaly Treatment Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of acromegaly treatment market with detailed market segmentation by disease, drug class, route of administration, distribution channel and geography. The global acromegaly treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading acromegaly treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global acromegaly treatment market is segmented on the basis of disease, drug class, route of administration and distribution channel. Based on disease, the market is segmented as ectopic acromegaly and pseudo acromegaly. Based on drug class the acromegaly treatment market is segmented as Somatostatin analogs (SSAS), Somatuline depot (lanreotide), others SSAs, dopamine agonists (DAs), bromocriptine mesylate, others DAs, growth hormone receptor antagonist (GHRAs) and somavert (Pegvisomant). On the basis of route of administration, the market is segmented into oral and parenteral On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global acromegaly treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The acromegaly treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting acromegaly treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the acromegaly treatment market in these regions.

MARKET PLAYERS
The reports cover key developments in the acromegaly treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from acromegaly treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for acromegaly treatment in the global market. Below mentioned is the list of few companies engaged in the acromegaly treatment market.

The report also includes the profiles of key acromegaly treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Novartis AG
  • Pfizer Inc.
  • Mylan N.V.
  • Zydus Pharmaceuticals, Inc.
  • Ipsen Pharma
  • Validus Pharmaceuticals LLC
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Fresenius Kabi
  • Foresee Pharmaceuticals LLC
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Acromegaly Treatment Market - By Disease
1.3.2 Acromegaly Treatment Market - By Drug Class
1.3.3 Acromegaly Treatment Market - By Route of Administration
1.3.4 Acromegaly Treatment Market - By Distribution Channel
1.3.5 Acromegaly Treatment Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ACROMEGALY TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ACROMEGALY TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ACROMEGALY TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. ACROMEGALY TREATMENT - GLOBAL MARKET OVERVIEW
6.2. ACROMEGALY TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ACROMEGALY TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE
7.1. OVERVIEW
7.2. DISEASE MARKET FORECASTS AND ANALYSIS
7.3. ECTOPIC ACROMEGALY
7.3.1. Overview
7.3.2. Ectopic Acromegaly Market Forecast and Analysis
7.4. PSEUDO ACROMEGALY
7.4.1. Overview
7.4.2. Pseudo Acromegaly Market Forecast and Analysis
8. ACROMEGALY TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. SOMATOSTATIN ANALOGS (SSAS)
8.3.1. Overview
8.3.2. Somatostatin Analogs (SSAS) Market Forecast and Analysis
8.4. SOMATULINE DEPOT (LANREOTIDE)
8.4.1. Overview
8.4.2. Somatuline Depot (lanreotide) Market Forecast and Analysis
8.5. OTHERS SSAS
8.5.1. Overview
8.5.2. Others SSAs Market Forecast and Analysis
8.6. DOPAMINE AGONISTS (DAS)
8.6.1. Overview
8.6.2. Dopamine Agonists (DAs) Market Forecast and Analysis
8.7. BROMOCRIPTINE MESYLATE
8.7.1. Overview
8.7.2. Bromocriptine Mesylate Market Forecast and Analysis
8.8. OTHERS DAS
8.8.1. Overview
8.8.2. Others DAs Market Forecast and Analysis
8.9. GROWTH HORMONE RECEPTOR ANTAGONIST (GHRAS)
8.9.1. Overview
8.9.2. Growth Hormone Receptor Antagonist (GHRAs) Market Forecast and Analysis
8.10. SOMAVERT (PEGVISOMANT)
8.10.1. Overview
8.10.2. Somavert (Pegvisomant) Market Forecast and Analysis
9. ACROMEGALY TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. PARENTERAL
9.4.1. Overview
9.4.2. Parenteral Market Forecast and Analysis
10. ACROMEGALY TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
10.1. OVERVIEW
10.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
10.3. HOSPITAL PHARMACIES
10.3.1. Overview
10.3.2. Hospital Pharmacies Market Forecast and Analysis
10.4. RETAIL PHARMACIES
10.4.1. Overview
10.4.2. Retail pharmacies Market Forecast and Analysis
10.5. ONLINE PHARMACIES
10.5.1. Overview
10.5.2. Online Pharmacies Market Forecast and Analysis
11. ACROMEGALY TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Acromegaly Treatment Market Overview
11.1.2 North America Acromegaly Treatment Market Forecasts and Analysis
11.1.3 North America Acromegaly Treatment Market Forecasts and Analysis - By Disease
11.1.4 North America Acromegaly Treatment Market Forecasts and Analysis - By Drug Class
11.1.5 North America Acromegaly Treatment Market Forecasts and Analysis - By Route of Administration
11.1.6 North America Acromegaly Treatment Market Forecasts and Analysis - By Distribution Channel
11.1.7 North America Acromegaly Treatment Market Forecasts and Analysis - By Countries
11.1.7.1 United States Acromegaly Treatment Market
11.1.7.1.1 United States Acromegaly Treatment Market by Disease
11.1.7.1.2 United States Acromegaly Treatment Market by Drug Class
11.1.7.1.3 United States Acromegaly Treatment Market by Route of Administration
11.1.7.1.4 United States Acromegaly Treatment Market by Distribution Channel
11.1.7.2 Canada Acromegaly Treatment Market
11.1.7.2.1 Canada Acromegaly Treatment Market by Disease
11.1.7.2.2 Canada Acromegaly Treatment Market by Drug Class
11.1.7.2.3 Canada Acromegaly Treatment Market by Route of Administration
11.1.7.2.4 Canada Acromegaly Treatment Market by Distribution Channel
11.1.7.3 Mexico Acromegaly Treatment Market
11.1.7.3.1 Mexico Acromegaly Treatment Market by Disease
11.1.7.3.2 Mexico Acromegaly Treatment Market by Drug Class
11.1.7.3.3 Mexico Acromegaly Treatment Market by Route of Administration
11.1.7.3.4 Mexico Acromegaly Treatment Market by Distribution Channel
11.2. EUROPE
11.2.1 Europe Acromegaly Treatment Market Overview
11.2.2 Europe Acromegaly Treatment Market Forecasts and Analysis
11.2.3 Europe Acromegaly Treatment Market Forecasts and Analysis - By Disease
11.2.4 Europe Acromegaly Treatment Market Forecasts and Analysis - By Drug Class
11.2.5 Europe Acromegaly Treatment Market Forecasts and Analysis - By Route of Administration
11.2.6 Europe Acromegaly Treatment Market Forecasts and Analysis - By Distribution Channel
11.2.7 Europe Acromegaly Treatment Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Acromegaly Treatment Market
11.2.7.1.1 Germany Acromegaly Treatment Market by Disease
11.2.7.1.2 Germany Acromegaly Treatment Market by Drug Class
11.2.7.1.3 Germany Acromegaly Treatment Market by Route of Administration
11.2.7.1.4 Germany Acromegaly Treatment Market by Distribution Channel
11.2.7.2 France Acromegaly Treatment Market
11.2.7.2.1 France Acromegaly Treatment Market by Disease
11.2.7.2.2 France Acromegaly Treatment Market by Drug Class
11.2.7.2.3 France Acromegaly Treatment Market by Route of Administration
11.2.7.2.4 France Acromegaly Treatment Market by Distribution Channel
11.2.7.3 Italy Acromegaly Treatment Market
11.2.7.3.1 Italy Acromegaly Treatment Market by Disease
11.2.7.3.2 Italy Acromegaly Treatment Market by Drug Class
11.2.7.3.3 Italy Acromegaly Treatment Market by Route of Administration
11.2.7.3.4 Italy Acromegaly Treatment Market by Distribution Channel
11.2.7.4 Spain Acromegaly Treatment Market
11.2.7.4.1 Spain Acromegaly Treatment Market by Disease
11.2.7.4.2 Spain Acromegaly Treatment Market by Drug Class
11.2.7.4.3 Spain Acromegaly Treatment Market by Route of Administration
11.2.7.4.4 Spain Acromegaly Treatment Market by Distribution Channel
11.2.7.5 United Kingdom Acromegaly Treatment Market
11.2.7.5.1 United Kingdom Acromegaly Treatment Market by Disease
11.2.7.5.2 United Kingdom Acromegaly Treatment Market by Drug Class
11.2.7.5.3 United Kingdom Acromegaly Treatment Market by Route of Administration
11.2.7.5.4 United Kingdom Acromegaly Treatment Market by Distribution Channel
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Acromegaly Treatment Market Overview
11.3.2 Asia-Pacific Acromegaly Treatment Market Forecasts and Analysis
11.3.3 Asia-Pacific Acromegaly Treatment Market Forecasts and Analysis - By Disease
11.3.4 Asia-Pacific Acromegaly Treatment Market Forecasts and Analysis - By Drug Class
11.3.5 Asia-Pacific Acromegaly Treatment Market Forecasts and Analysis - By Route of Administration
11.3.6 Asia-Pacific Acromegaly Treatment Market Forecasts and Analysis - By Distribution Channel
11.3.7 Asia-Pacific Acromegaly Treatment Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Acromegaly Treatment Market
11.3.7.1.1 Australia Acromegaly Treatment Market by Disease
11.3.7.1.2 Australia Acromegaly Treatment Market by Drug Class
11.3.7.1.3 Australia Acromegaly Treatment Market by Route of Administration
11.3.7.1.4 Australia Acromegaly Treatment Market by Distribution Channel
11.3.7.2 China Acromegaly Treatment Market
11.3.7.2.1 China Acromegaly Treatment Market by Disease
11.3.7.2.2 China Acromegaly Treatment Market by Drug Class
11.3.7.2.3 China Acromegaly Treatment Market by Route of Administration
11.3.7.2.4 China Acromegaly Treatment Market by Distribution Channel
11.3.7.3 India Acromegaly Treatment Market
11.3.7.3.1 India Acromegaly Treatment Market by Disease
11.3.7.3.2 India Acromegaly Treatment Market by Drug Class
11.3.7.3.3 India Acromegaly Treatment Market by Route of Administration
11.3.7.3.4 India Acromegaly Treatment Market by Distribution Channel
11.3.7.4 Japan Acromegaly Treatment Market
11.3.7.4.1 Japan Acromegaly Treatment Market by Disease
11.3.7.4.2 Japan Acromegaly Treatment Market by Drug Class
11.3.7.4.3 Japan Acromegaly Treatment Market by Route of Administration
11.3.7.4.4 Japan Acromegaly Treatment Market by Distribution Channel
11.3.7.5 South Korea Acromegaly Treatment Market
11.3.7.5.1 South Korea Acromegaly Treatment Market by Disease
11.3.7.5.2 South Korea Acromegaly Treatment Market by Drug Class
11.3.7.5.3 South Korea Acromegaly Treatment Market by Route of Administration
11.3.7.5.4 South Korea Acromegaly Treatment Market by Distribution Channel
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Acromegaly Treatment Market Overview
11.4.2 Middle East and Africa Acromegaly Treatment Market Forecasts and Analysis
11.4.3 Middle East and Africa Acromegaly Treatment Market Forecasts and Analysis - By Disease
11.4.4 Middle East and Africa Acromegaly Treatment Market Forecasts and Analysis - By Drug Class
11.4.5 Middle East and Africa Acromegaly Treatment Market Forecasts and Analysis - By Route of Administration
11.4.6 Middle East and Africa Acromegaly Treatment Market Forecasts and Analysis - By Distribution Channel
11.4.7 Middle East and Africa Acromegaly Treatment Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Acromegaly Treatment Market
11.4.7.1.1 South Africa Acromegaly Treatment Market by Disease
11.4.7.1.2 South Africa Acromegaly Treatment Market by Drug Class
11.4.7.1.3 South Africa Acromegaly Treatment Market by Route of Administration
11.4.7.1.4 South Africa Acromegaly Treatment Market by Distribution Channel
11.4.7.2 Saudi Arabia Acromegaly Treatment Market
11.4.7.2.1 Saudi Arabia Acromegaly Treatment Market by Disease
11.4.7.2.2 Saudi Arabia Acromegaly Treatment Market by Drug Class
11.4.7.2.3 Saudi Arabia Acromegaly Treatment Market by Route of Administration
11.4.7.2.4 Saudi Arabia Acromegaly Treatment Market by Distribution Channel
11.4.7.3 U.A.E Acromegaly Treatment Market
11.4.7.3.1 U.A.E Acromegaly Treatment Market by Disease
11.4.7.3.2 U.A.E Acromegaly Treatment Market by Drug Class
11.4.7.3.3 U.A.E Acromegaly Treatment Market by Route of Administration
11.4.7.3.4 U.A.E Acromegaly Treatment Market by Distribution Channel
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Acromegaly Treatment Market Overview
11.5.2 South and Central America Acromegaly Treatment Market Forecasts and Analysis
11.5.3 South and Central America Acromegaly Treatment Market Forecasts and Analysis - By Disease
11.5.4 South and Central America Acromegaly Treatment Market Forecasts and Analysis - By Drug Class
11.5.5 South and Central America Acromegaly Treatment Market Forecasts and Analysis - By Route of Administration
11.5.6 South and Central America Acromegaly Treatment Market Forecasts and Analysis - By Distribution Channel
11.5.7 South and Central America Acromegaly Treatment Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Acromegaly Treatment Market
11.5.7.1.1 Brazil Acromegaly Treatment Market by Disease
11.5.7.1.2 Brazil Acromegaly Treatment Market by Drug Class
11.5.7.1.3 Brazil Acromegaly Treatment Market by Route of Administration
11.5.7.1.4 Brazil Acromegaly Treatment Market by Distribution Channel
11.5.7.2 Argentina Acromegaly Treatment Market
11.5.7.2.1 Argentina Acromegaly Treatment Market by Disease
11.5.7.2.2 Argentina Acromegaly Treatment Market by Drug Class
11.5.7.2.3 Argentina Acromegaly Treatment Market by Route of Administration
11.5.7.2.4 Argentina Acromegaly Treatment Market by Distribution Channel
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ACROMEGALY TREATMENT MARKET, KEY COMPANY PROFILES
13.1. NOVARTIS AG
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. PFIZER INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. MYLAN N.V.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. ZYDUS PHARMACEUTICALS, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. IPSEN PHARMA
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. VALIDUS PHARMACEUTICALS LLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. SANDOZ INTERNATIONAL GMBH
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. FRESENIUS KABI
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. FORESEE PHARMACEUTICALS LLC
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. Pfizer Inc.
3. Mylan N.V.
4. Zydus Pharmaceuticals, Inc.
5. Ipsen Pharma
6. Validus Pharmaceuticals LLC
7. Teva Pharmaceutical Industries Ltd.
8. Sandoz International GmbH
9. Fresenius Kabi
10. Foresee Pharmaceuticals LLC